Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Roche Seen Offering NICE Further Price Cut For MS Drug Ocrevus

UK HTA provisionally tells Roche price for supplying MS blockbuster Ocrevus to the NHS not good enough – 'try again'.

Approvals Commercial Companies
Advertisement

Market Access

Set Alert for Market Access

Latest From Market Access

Rigel Readies Tavalisse For Late-May Launch After FDA Approval

Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.

Approvals Immune Disorders

Call For India Compulsory Licenses For Last Resort TB Drugs

Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses. 

India Policy & Regulation

Amazon And The Case For Major Health Care Disruption

From drug delivery by drone to busting the drug rebate model, panelists at CNBC's inaugural health care conference had big visions for the changes Amazon could bring to health care.

Distribution Business Strategies

J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says

Bernstein analyst looks into J&J's average net price decline in 2017 and notes average sales price hikes for growth products Darzalex and Imbruvica are offset by price cuts for drugs facing competition. All products had single digit increases, though.
Pricing Strategies Pharmacy Benefit Management

Drug Pricing: A Game Of Chutes & Ladders

The US drug pricing policy environment is facing changes. Much of the action, whether Congressional or regulatory, is good for industry – but there have been a few setbacks and more may come.

Market Access Pricing Debate

The Ups and Downs Of US Drug Pricing Policy

If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.

Pricing Debate Market Access
See All
UsernamePublicRestriction

Register